Delivery of ATRA and Gefitinib by Polyphenylalanine Nanosystem to Overcome EGFR-TKI Resistance in Lung Adenocarcinoma

被引：0
|
作者：
Liu, S. [1 ]
Zhou, H. [2 ]
Xu, B. [1 ]
Deng, J. [1 ]
Zeng, F. [2 ]
Qiu, H. [2 ]
机构：
[1] Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Thorac Surg, Guangzhou, Peoples R China
[2] Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Gen Practice, Guangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Polyphenylalanine; EGFR-TKI resistance; Non-small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.08-04
引用
收藏
页码：S198 / S198
页数：1
相关论文
共 50 条
  • [31] MOLECULAR MECHANISMS OF EGFR-TKI RESISTANCE AND STRATEGY WITH HGF-MET INHIBITORS TO OVERCOME THE RESISTANCE
    Yano, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 12 - 12
  • [32] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S980 - S981
  • [33] Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
    Yamaoka, Toshimitsu
    Ohmori, Tohru
    Ohba, Motoi
    Arata, Satoru
    Kishino, Yasunari
    Murata, Yasunori
    Kusumoto, Sojiro
    Ishida, Hiroo
    Shirai, Takao
    Hirose, Takashi
    Ohnishi, Tsukasa
    Sasaki, Yasutsuna
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (12) : 3040 - 3054
  • [34] RELEVANCE BETWEEN CEA LEVEL AND EGFR MUTATION, EFFICACY OF EGFR-TKI IN PATIENTS WITH LUNG ADENOCARCINOMA
    Zhang, Wei Y.
    Han, Hui B.
    Jin, Bo
    Shao, Hua M.
    Dong, Yu
    Huang, Mi A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S891 - S891
  • [35] The IASLC Grading System as a Predictor For EGFR-TKI Therapy in EGFR-Mutant Lung Adenocarcinoma
    Deng, C.
    Chen, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S175 - S175
  • [36] NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKI
    Facchinetti, Francesco
    Tiseo, Marcello
    Gnetti, Letizia
    Silini, Enrico Maria
    Ardizzoni, Andrea
    LUNG CANCER, 2013, 82 (01) : 177 - 178
  • [37] EXPRESSION OF NOTCH-1 IN EGFR-TKI ACQUIRED RESISTANT LUNG ADENOCARCINOMA
    Xie, M.
    He, C. -S.
    Hou, J. -H.
    ANNALS OF ONCOLOGY, 2013, 24
  • [38] EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study
    Gieszer, Balazs
    Megyesfalvi, Zsolt
    Dulai, Viktoria
    Papay, Judit
    Kovalszky, Ilona
    Timar, Jozsef
    Fillinger, Janos
    Harko, Tunde
    Pipek, Orsolya
    Teglasi, Vanda
    Regos, Eszter
    Papp, Gergo
    Szallasi, Zoltan
    Laszlo, Viktoria
    Renyi-Vamos, Ferenc
    Galffy, Gabriella
    Bodor, Csaba
    Dome, Balazs
    Moldvay, Judit
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (02) : 662 - +
  • [39] Outcomes of EGFR-TKI therapy in EGFR mutated metastatic lung adenocarcinoma in an inner city population
    Thekkekara, Romy Jose
    Kumar, Rohit
    Lad, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Epithelial-Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma
    Uramoto, Hidetaka
    Iwata, Teruo
    Onitsuka, Takamitsu
    Shimokawa, Hidehiko
    Hanagiri, Takeshi
    Oyama, Tsunehiro
    ANTICANCER RESEARCH, 2010, 30 (07) : 2513 - 2517
12345